Skip to content

Vidatalk Communication Application: Usability, Acceptability and Efficacy Study

Improving Outcomes for Mechanically Ventilated Patients With the Digital EZ Board

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02921776
Enrollment
147
Registered
2016-10-03
Start date
2018-02-19
Completion date
2019-06-11
Last updated
2022-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critical Illness, Nonverbal Communication

Keywords

Vidatalk, App, Augmentative and Alternative Communication, iPad, Android, Mechanical ventilation, Patient Communication, Critical Illness

Brief summary

This Phase II Small Business Technology Transfer Research (STTR) will deliver a comprehensive patient communication solution for communication-impaired patients in the intensive care unit that may help decrease days in delirium, decrease anxiety levels, and reduce sedation exposure which are proximal outcomes known to be associated with decreased mechanical ventilation days, shorter lengths of ICU and hospital stay, and lower healthcare cost. The primary goal of this Phase II STTR proposal is to further define user requirements and product specifications and develop a prototype of VidaTalk, a patient-centric, touch pad communication software, to provide mechanically ventilated (MV) patients an evidence-based solution for effectively communicating their needs to care providers and family. A secondary goal is to test the impact of the VidaTalk on clinical outcomes. This study will use mixed methods including observations and interaction with hospitalized patients as they use the VidaTalk tool, surveys and medical record data extraction, product evaluation and brief interview, satisfaction surveys with family members of ICU patients, and focus groups with Registered Nurses. Specific Aim 1. Develop a commercial prototype of VidaTalk that will include multilingual and customizable messages, compatibility with tablet devices, picture symbols, and integration with mobile communication devices. Specific Aim 2. Demonstrate usability with iterative user assessment testing in a clinical setting. Specific Aim 3. Test the clinical efficacy of VidaTalk via android application with MV patients by examining qualitative and quantitative endpoints in a clinical setting. Aim 3 hypothesis: MV patients using VidaTalk will demonstrate significant reductions in patient-reported communication difficulty and frustration, anxiety, sedation exposure, delirium/coma-free days, and improved patient and family satisfaction with ICU care compared to MV patients receiving attention-control (i.e., tablets with health education application). Specific Aim 4. Validation of electronic visual analogue scale, versus current standard paper scale. Specific Aim 5 a, b and c. Test the effect of the communication tablet (VidaTalk) on psychological symptoms in family caregivers.

Detailed description

Treatment-induced communication impairment is one of the most common and distressful symptoms to mechanically ventilated intensive care unit (ICU) patients and is associated with anxiety, panic, anger, frustration, sleeplessness, and distress.This Phase II Small Business Technology Transfer Research (STTR) will deliver a comprehensive solution that may help decrease days in delirium, decrease anxiety levels, and reduce sedation exposure which are proximal outcomes known to be associated with decreased mechanical ventilation days, shorter lengths of ICU and hospital stay, and lower healthcare cost. The primary goal of this Phase II STTR proposal is to further define user requirements and product specifications and develop a prototype of VidaTalk (previously TouchTalk), a patient-centric, touch pad communication software, to provide mechanically ventilated (MV) patients an evidence-based solution for effectively communicating their needs to care providers and family. A secondary goal is to test the impact of the VidaTalk on clinical outcomes (e.g., patient-reported communication difficulty and frustration, anxiety, sedation exposure, delirium/coma-free days, and improved patient and family satisfaction with ICU care). This study will use mixed methods including observations and interaction with hospitalized patients as they use the VidaTalk communication tool, surveys and medical record data extraction, product evaluation and brief interview, satisfaction survey with family members of ICU patients and focus groups with Registered Nurses. Our Phase I STTR successfully delivered a beta prototype that met technical feasibility criteria; however, additional requirements emerged as a common theme from user testing and market analysis. The current study will meet the identified needs for VidaTalk to operate on android devices, be customizable to patients' unique message needs, use pictures symbols for communication, and be able to route patient requests to providers who are not present at the bedside. Specific Aim 1 (Preliminary to Clinical Trial). Develop a commercial prototype of VidaTalk that will include multilingual and customizable messages, compatibility with tablet devices, picture symbols, and integration with mobile communication devices. Specific Aim 2 (Preliminary to Clinical Trial). Demonstrate usability with iterative user assessment testing in a clinical setting. Specific Aim 3. Test the clinical efficacy of VidaTalk via android application with MV patients by examining qualitative and quantitative endpoints in a clinical setting. Aim 3 hypothesis: MV patients using VidaTalk will demonstrate notable reductions in patient-reported frustration and communication difficulty, anxiety, sedation exposure, delirium/coma-free days, and improved patient and family satisfaction with ICU care compared to MV patients receiving attention-control. Specific Aim 4. Validation of electronic visual analogue scale, versus current standard paper scale. Specific Aim 5. Test the effect of the communication tablet (VidaTalk) on psychological symptoms in family caregivers.

Interventions

OTHERAim 1 - VidaTalk - post-extubation

Observation of task completion will be made while patients complete a series of messages using the VidaTalk app: * Tell me you are tired * Tell me you are having pain * Rate this pain * Tell me there is pain in your back * Tell me your pain is sharp * Ask to see the doctor * Write your favorite color by drawing with your finger * Type How are you? Patients will also complete a 1-item difficulty rating and a 3-item After-Scenario Questionnaire (ASQ) after each task. Patients will also be asked to (a) comment on the customization of the app and make suggestions; (b) rate the extent to which they would use the device if they were an ICU patient and unable to speak. Group 1 only: Patients will be asked about their preferences for customizing the VidaTalk app.

OTHERAim 2 - VidaTalk - intubated

Usability testing prior to clinical trial. The company will have performed further iterative design assessments and engineered a Vidatalk tablet application prototype for a field-test for functionality (human-device interaction factors, feasibility, and usability) and acceptability. Data will be collected by a trained data collector as in Aim 1 with the addition of Ease of Communication and Frustration ratings before and after the testing sequence. To reduce burden, patients in this group will complete the 3-item ASQ one time after all tasks are completed. They will also complete a 13-item System Usability Scale (SUS).

DEVICEAim 3 - VidaTalk tablet app

Patients in the intervention group will receive a protocolized instruction in the use of the VidaTalk application and mounting of the device including patient return demonstration of key features, and review/ testing to competence conducted by a trained interventionist. When available, a family member may be included in surveys about the patients hospital stay, if patient agrees. The interventionist will visit patients briefly (5-10 minutes) each day to check user needs and concerns and will review or retrain on message options if needed.

OTHERAim 3 - attention-control with non-VidaTalk tablet

Patents randomized to the control group will receive a protocolized introduction to the bedside Android device without the VidaTalk app, focusing instead on a common tablet application. Daily visits will be conducted with control group patients to query on use of the attention-control tablet.

Sponsors

Vidatak, LLC
CollaboratorINDUSTRY
Ohio State University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

Aim 1: Inclusion Criteria: 1. ≥18 years old 2. Able to communicate in English 3. Awake alert, responding appropriately to commands. 4. Normal (aided or unaided) hearing and vision 5. Able to control head, arm and hand movements 6. Physiologically stable and in no acute distress (per nurse report)

Exclusion criteria

1. Pre-existing communication impairments 2. Diagnosis of severe dementia or brain injury 3. CAM-ICU positive for delirium 4. unresponsiveness or inattention Aim 2: Inclusion Criteria: 1. ≥18 years old 2. Able to communicate in English 3. Awake alert, responding appropriately to commands. 4. Normal (aided or unaided) hearing and vision 5. Able to control head, arm and hand movements 6. Physiologically stable and in no acute distress (per nurse report) 7. Intubated via oral endotracheal or tracheal tube without speaking valve, receiving mechanical ventilation

Design outcomes

Primary

MeasureTime frameDescription
Mean Daily Patient-reported Communication Difficulty Rating Using Single Item 0-4 Rating ScaleDaily post-randomization until extubation or ICU discharge up to maximum of 28 days in the ICUAim 3 - Mean item score of daily by patient self report using a single item Likert-type scale from the Ease of Communication Scale (ECS) where scores range from 0 not hard at all to 4 extremely hard

Secondary

MeasureTime frameDescription
Mean Patient Frustration With CommunicationDaily post-randomization until extubation or ICU discharge up to maximum of 28 days in the ICUAim 3 - This will be the calculated mean of the daily Communication Frustration scale - a single item scale reported by the patient, ranging from 0 not frustrating to 4 extremely frustrating
Mean Daily Sedation ExposureDaily post-randomization until extubation or ICU discharge up to maximum of 28 days in the ICU daily in ICUUsed in Aim 3 only. Calculation of benzodiazepine and morphine equivalents (for opiates) using hospital conversion charts (pharmacy conversion chart). All benzo IV doses were converted to Lorazepam IV doses. All opioid IV doses were converted to morphine IV doses. All benzo oral doses were converted to Lorazepam oral doses. All opioid oral doses were converted to morphine oral doses. Oral doses were converted to IV equivalents. Summed doses of Lorazepam IV and morphine IV were calculated for each study day for each patient. Doses were converted to milligrams per kilogram based on the patient's body weight. Higher numbers indicate greater sedation and/or opiate exposure.
Ease of Communication at Extubation /ICU Dischargemeasured at Extubation /ICU DischargeEase of Communication Scale -10-item likert scale total score ranging from 0-40. Each item is 0-4 likert scale, total score is sum of all items with higher scores indicating greater communication difficulty.
Percentage of Patients Scoring in the Calm Range During Study Days on Richmond Agitation Sedation ScoreDaily post-randomization until extubation or ICU discharge up to maximum of 28 days in the ICUThe Richmond Agitation Sedation Scale, a 10-level observational rating of agitation-sedation motor activity ranging from +4 'combative' to -5 unresponsive, with 0 as calm. Since this is a categorical measure, we compared proportion of patients with RASS in -1 to +1 (calm) range during study days.
Delirium/Coma -Free DaysDaily, from enrollment to 28 days post-enrollmentAim 3 -Delirium/coma-free days is defined as the number of days alive and free of delirium and coma during the 28-day study period. Delirium will be coded as present when a patient displays both features 1 and 2, and either 3 or 4 of the CAM-ICU (Confusion Assessment Method). Coma is defined as a RASS (Richmond Agitation-Sedation Scale ) assessment score of -4 or -5.
Family Satisfaction With Care in the Intensive Care Unit FS-ICUOne 10 minute survey will be given at patient's ICU discharge or extubation(Aim3 )The Family Satisfaction with ICU Care (FS-ICU 24R) questionnaire overall satisfaction score is derived from questions 1 through 24 (26 items) and combines two subscale summary scores. The satisfaction with care summary score is derived from the questions numbered 1 through 14 (which consists of 16 questions because question 2 has parts a, b and c). The satisfaction with decision making summary score is derived from questions 15 through 24 (10 questions). All questions are coded as integers from 1 (worst) to 5 (best). Rescale the summary scores from 1 through 5 to 0 through 100 by subtracting 1 from the scores (so they can range from 0 to 4) and then multiplying each score by 25.
Electronic Visual Analogue Scale-validation MeasureOnly measured at baseline, order of administration randomized before or after paper version(Aim4) visual analogue touch screen scale via android tablet with REDCap link. Not able to calculate because the touch screen scale was unreliable. Patients often needed assistance with the touch screen cursor for this experimental measure. We determined that pencil and paper analogue scale was superior for this patient population.
Patient Satisfaction With CareMeasured at extubation or discharge from ICU which ever comes firstA 24-item survey with lower scores indicating greater satisfaction with care.
Family Member AnxietyBaseline, patient extubation or discharge from ICU, 1-month, 3-month, 6-month post-discharge(Aim 5) Hospital Anxiety and Depression Scale (HADS) Anxiety sub scale including 7 items each scored from 0-3 with total scores ranging from 0 - 21 with higher scores indicating higher levels of anxiety.
Mean Patient Reported Anxiety Score Using Visual Analogue ScaleDaily post-randomization until extubation or ICU discharge up to maximum of 28 days in the ICUAim 3 - Calculated mean of daily measure by patient mark (x) or point on the Visual Analogue Scale for anxiety, a 100 mm vertical line ranging from 0 (not anxious at all) to 10 (most anxious I've ever been).
Post-traumatic Stress Symptoms: Impact of Events Scale-revised (IES-R)1-month, 3-month, 6-month post-discharge(Aim 5) Impact of Events Scale-revised. The IES-R is a 22-item self-report instrument with three subscales including intrusion (8 items), avoidance (8 items), and hyperarousal (6 items). The respondent is asked to report the degree of distress experienced for each item in the past 7 days. Each item is scored on a five-point Likert scale (0, not at all; 1, rarely; 2, occasionally; 3, fairly often; and 4, often) and total scores range from 0 to 88. Higher scores are representative of greater distress.
Family Communication Difficultybaseline and extubation or discharge from the ICUFamily Communication Survey administered to participant families. Sum of 9-items with each item rating 0 (not at all) to 4 (extremely difficult), resulting in a total summed score from 0 - 36. Higher scores indicate greater difficulty.
Communication Task Error RateMeasured during 30-60 minute usability testing visit which occurs at study completion. This outcome applies only to Aim 1 & 2 arms.Aims 1 & 2 - count of the number of errors recorded by video screen capture for each of 8 communication tasks. Individual patients ranged from 0 to 9 errors, however this measure contains no upper range per task as it is a count of actual observed errors committed by patients.
Total Error RateMeasured during 30-60 minute usability testing visit which occurs at study completionAims 1 & 2 - calculated mean of the total number of errors recorded by video screen capture divided by the number of communication tasks completed (8 maximum) Aim 1 extubated patients. Using group 1 and group 2 summary data, 11 patients completed 82 tasks (6 were abandoned, 5 of these by one patient). Removing abandonments, total number of errors = 25/ 82 tasks = 0.30 error rate. Aim 2 intubated patients. 11 patients completed 69 tasks (18 were abandoned; 1 task was refused). Removing abandonments, total number of errors = 60/ 69 tasks = 0.87error rate.
Patient Satisfaction With Communication Task EaseMeasured during 30-60 minute usability testing visit which occurs at study completionAims 1 & 2 - a single item from the After Scenario Questionnaire (ASQ) of patient's self rating of satisfaction with the ease of completing each of 8 communication tasks on the usability test. Question asked of patients was Overall, I am satisfied with the ease of completing this task. 1-strongly disagree 7-strongly agree. Higher scores indicated greater satisfaction with the ease of completing the task.
Observed Task Completion Time (in Seconds)Measured during 30-60 minute usability testing visit which occurs at study completionAims 1 & 2 - This is the time, measured in seconds, on the screen capture recording beginning with the communication task command to patient completion of the communication task or message to patient completion of each of the 8 communication tasks on the usability test, calculated from the screen capture recordings
After-Scenario Questionnaire (ASQ) ScoreMeasured during 30-60 minute usability testing visit which occurs at study completionAims 1 & 2. The After-Scenario Questionnaire (ASQ) is a 3-item likert-type scale used to assess how difficult a user perceived a task in a usability test. Responses range from 1-strongly disagree to 7- strongly agree. Total score is the sum of the 3 items, possible scores range from 3 to 21. Higher scores indicated better outcomes. This was not measured for each task as that was too burdensome for intubated patients. We measured once as an overall rating at the end of the session- 3-item ASQ.
System Usability Scale (SUS) -AdaptedMeasured during 30-60 minute usability testing visit which occurs at study completionAims 1 & 2, System Usability Scale is 13-item likert type scale with item ratings of 1 'strongly agree' to 7 'strongly disagree' to obtain the patient's rating of overall usability of the VidaTalk application, total scores range from 13 to 91 Note: This is different from the standard 10-item SUS that uses a 5-point scale, with scores ranging 0-100.
Number of Participants That Responded Yes to Having Communication Difficulty at Extubation or ICU Dischargemeasured at Extubation /ICU DischargeMeasured as a single item : Question asked was - Presence of communication difficulty in the last few days? with answers being Yes or No
Family Member DepressionBaseline, patient extubation or discharge from ICU, 1-month, 3-month, 6-month post-discharge(Aim 5). Hospital Anxiety and Depression Scale (HADS-D)- Depression Subscale including 7 items each scored from 0-3 with total scores ranging from 0 - 21 with higher scores indicating higher levels of depression symptoms.

Countries

United States

Participant flow

Recruitment details

Patients were screened for eligibility by critical care research coordinators and referred to the study coordinator and research assistant for bedside eligibility screening and recruitment.

Participants by arm

ArmCount
Aim 1- VidaTalk Post-extubation
Preliminary to clinical trial. Grp1+ Grp2 will each consist of five previously mechanically ventilated patients recruited from the ICUs at the OSUWMC. Grp 1 will use an initial android prototype of VidaTalk tablet application assessed for functionality + usability on a series of scripted communication tasks. Grp 2 will use an improved alpha prototype of VidaTalk tablet application version engineered from observations made during Grp 1 sessions. Aim 1 - VidaTalk - post-extubation: Observation of task completion will be made while patients complete messages using the VidaTalk app: Tired, Pain - rating, location, quality, Ask for doctor, Finger writing, Keyboard phrase. Patients will also complete 1-item difficulty rating + 3-item After-Scenario Questionnaire after each task. Patients will rate the extent to which they would use the device if they were an ICU patient unable to speak. Grp 1 only: will be asked their preferences for customizing the app.
13
Aim 2 - VidaTalk Intubated
Usability testing preliminary to Clinical Trial. Mechanically Ventilated patients will provide feedback on acceptability, will perform test messages with minimal errors, and will rate VidaTalk an overall average score of 4.5 or higher (Likert-type scale; 1 to 7) on usability questions. Prior to implementing these procedures, the company will perform further iterative design assessments and engineer a Vidatalk tablet application prototype. This prototype will be used with a final group of ten (10) intubated patients receiving mechanical ventilation support to field-test the prototype for functionality (human-device interaction factors, feasibility, and usability) and acceptability. Intervention is usability tasks with the VidaTalk app Aim 2 - VidaTalk - intubated: Usability testing prior to clinical trial. The company will have performed further iterative design assessments and engineered a Vidatalk tablet application prototype for a field-test for functionality (human-
23
Aim 3 - VidaTalk Tablet App
Test the clinical efficacy of VidaTalk with MV patients by examining qualitative & quantitative endpoints in a clinical setting. 35 intubated patients (oral endotracheal tube or tracheostomy) will be randomized to the intervention arm and will receive a protocolized instruction in the use of the VidaTalk application including patient return demonstration of key features, and review/ testing to competence conducted by a trained interventionist. When available, a family member may be included in surveys about the patients hospital stay, if patient agrees. The interventionist will visit patients briefly (5-10 minutes) each day to check user needs and concerns and will review or retrain on message options if needed. Intervention will be receipt of VidaTalk tablet application. Aim 3 - VidaTalk tablet app: Patients in the intervention group will receive a protocolized instruction in the use of the VidaTalk application and mounting of the device including patient return demonstration.
31
Aim 3 - Attention-control
35 intubated patients (oral endotracheal tube or tracheostomy) will receive the standard of care, which may include primarily writing tools (paper and pen) and, occasionally, picture or alphabet communication charts. Patients randomized to the control group will receive a protocolized introduction to the bedside Android device without the VidaTalk application, focusing instead on a common tablet application. Daily visits will be conducted with control group patients to query on use of the attention-control tablet. Interventions will be Aim 3 - attention-control with non-VidaTalk tablet. Aim 3 - attention-control with non-VidaTalk tablet: Patents randomized to the control group will receive a protocolized introduction to the bedside Android device without the VidaTalk app, focusing instead on a common tablet application. Daily visits will be conducted with control group patients to query on use of the attention-control tablet.
32
Aim 5-VidaTalk Efficacy in Family Caregivers- VidaTalk Group
Aim 5 will test the preliminary efficacy of VidaTalk compared to attention control (AC) on anxiety and depression symptoms in family caregivers during the ICU stay and post-discharge (1-mos; 3-mos; 6-mos) and PTSD-related symptoms post-discharge both qualitatively and quantitatively. Aim 5.a.) Psychological outcomes (anxiety, depression, and PTSD-related symptoms) between the two groups will be compared at each time point and across time. Aim 5.b.) Family caregivers' perceived communication difficulty will be measured Aim 5.c.) Family caregivers' experience of communication while they were visiting the patient who received the VidaTalk app in the ICU and their emotional reactions to communication with a patient will be measured.
18
Aim 5 Family Caregiver- Attention Control
Usual care condition for family communication with mechanically ventilated patients. Family caregivers receive tablet instruction sheet (no VidaTalk app). Family caregivers were asked to enter dates and times of visits into ICU bedside visitation log.
16
Total133

Withdrawals & dropouts

PeriodReasonFG000FG001FG002FG003FG004FG005FG006FG007
Overall StudyDeath00020000
Overall Studyextubation or early discharge00055000
Overall StudyLost to Follow-up00000236
Overall Studypatient deterioration, fatigue26000000
Overall StudyWithdrawal by Subject02011081

Baseline characteristics

CharacteristicAim 2 - VidaTalk IntubatedAim 3 - Attention-controlAim 1- VidaTalk Post-extubationAim 5-VidaTalk Efficacy in Family Caregivers- VidaTalk GroupAim 5 Family Caregiver- Attention ControlTotalAim 3 - VidaTalk Tablet App
Age, Continuous57.57 years
STANDARD_DEVIATION 13.41
53.6 years
STANDARD_DEVIATION 14.7
55.92 years
STANDARD_DEVIATION 15.4
48.94 years
STANDARD_DEVIATION 15.84
50.69 years
STANDARD_DEVIATION 15.89
52.9 years
STANDARD_DEVIATION 14.1
52.1 years
STANDARD_DEVIATION 13.7
Education
High school graduate or less
12 Participants13 Participants4 Participants5 Participants5 Participants58 Participants19 Participants
Education
Some college
7 Participants19 Participants7 Participants13 Participants11 Participants69 Participants12 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
23 Participants32 Participants13 Participants18 Participants16 Participants133 Participants31 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants
Family Caregiver Anxiety9.22 units on a scale
STANDARD_DEVIATION 5.02
9.25 units on a scale
STANDARD_DEVIATION 4.49
9.24 units on a scale
STANDARD_DEVIATION 4.71
Family Caregiver Depression5.89 units on a scale
STANDARD_DEVIATION 3.85
5.25 units on a scale
STANDARD_DEVIATION 4.17
5.59 units on a scale
STANDARD_DEVIATION 3.96
Family Communication Survey25.94 units on a scale
STANDARD_DEVIATION 6.24
24.93 units on a scale
STANDARD_DEVIATION 5.57
25.47 units on a scale
STANDARD_DEVIATION 5.87
Intubation Method
oral intubation
8 Participants16 Participants39 Participants15 Participants
Intubation Method
tracheostomy
11 Participants16 Participants43 Participants16 Participants
Patient Anxiety6.4 units on a scale
STANDARD_DEVIATION 3.1
6.2 units on a scale
STANDARD_DEVIATION 3
5.9 units on a scale
STANDARD_DEVIATION 3
Patient Communication Difficulty3.33 units on a scale
STANDARD_DEVIATION 0.84
3.4 units on a scale
STANDARD_DEVIATION 0.9
3.8 units on a scale
STANDARD_DEVIATION 0.63
3.3 units on a scale
STANDARD_DEVIATION 1.1
3.1 units on a scale
STANDARD_DEVIATION 1.2
Patient Frustration with Communication2.94 units on a scale
STANDARD_DEVIATION 1.35
3.9 units on a scale
STANDARD_DEVIATION 0.3
3.6 units on a scale
STANDARD_DEVIATION 1.26
3.6 units on a scale
STANDARD_DEVIATION 0.7
3.4 units on a scale
STANDARD_DEVIATION 1
Physical Restraint8 Participants13 Participants5 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants1 Participants0 Participants1 Participants0 Participants
Race (NIH/OMB)
Black or African American
2 Participants4 Participants0 Participants5 Participants3 Participants19 Participants5 Participants
Race (NIH/OMB)
More than one race
1 Participants0 Participants1 Participants0 Participants0 Participants2 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
20 Participants28 Participants12 Participants12 Participants13 Participants111 Participants26 Participants
severity of illness72.8 units on a scale
STANDARD_DEVIATION 26.55
77.0 units on a scale
STANDARD_DEVIATION 27.2
65.0 units on a scale
STANDARD_DEVIATION 17.82
76.3 units on a scale
STANDARD_DEVIATION 24.5
75.6 units on a scale
STANDARD_DEVIATION 21.8
Sex: Female, Male
Female
9 Participants12 Participants5 Participants15 Participants15 Participants69 Participants13 Participants
Sex: Female, Male
Male
14 Participants20 Participants8 Participants3 Participants1 Participants64 Participants18 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
EG004
affected / at risk
EG005
affected / at risk
EG006
affected / at risk
EG007
affected / at risk
EG008
affected / at risk
deaths
Total, all-cause mortality
0 / 130 / 232 / 310 / 320 / 00 / 180 / 160 / 70 / 7
other
Total, other adverse events
0 / 130 / 230 / 310 / 320 / 00 / 180 / 160 / 70 / 7
serious
Total, serious adverse events
0 / 130 / 230 / 310 / 320 / 00 / 180 / 160 / 70 / 7

Outcome results

Primary

Mean Daily Patient-reported Communication Difficulty Rating Using Single Item 0-4 Rating Scale

Aim 3 - Mean item score of daily by patient self report using a single item Likert-type scale from the Ease of Communication Scale (ECS) where scores range from 0 not hard at all to 4 extremely hard

Time frame: Daily post-randomization until extubation or ICU discharge up to maximum of 28 days in the ICU

Population: This outcome is only for the clinical trial. Applies only to Aim 3 arms.

ArmMeasureValue (MEAN)Dispersion
Aim 3 - VidaTalk Tablet AppMean Daily Patient-reported Communication Difficulty Rating Using Single Item 0-4 Rating Scale3.10 score on a scaleStandard Deviation 1.98
Aim 3 - Attention-controlMean Daily Patient-reported Communication Difficulty Rating Using Single Item 0-4 Rating Scale3.28 score on a scaleStandard Deviation 1.9
p-value: 0.45t-test, 2 sided
Secondary

After-Scenario Questionnaire (ASQ) Score

Aims 1 & 2. The After-Scenario Questionnaire (ASQ) is a 3-item likert-type scale used to assess how difficult a user perceived a task in a usability test. Responses range from 1-strongly disagree to 7- strongly agree. Total score is the sum of the 3 items, possible scores range from 3 to 21. Higher scores indicated better outcomes. This was not measured for each task as that was too burdensome for intubated patients. We measured once as an overall rating at the end of the session- 3-item ASQ.

Time frame: Measured during 30-60 minute usability testing visit which occurs at study completion

Population: After Scenario Questionnaire is a 3-item patient rating of the usability of the VidaTalk communication application for each communication feature on ease, time, and support information

ArmMeasureGroupValue (MEAN)Dispersion
Aim 1- VidaTalk Post-extubationAfter-Scenario Questionnaire (ASQ) ScoreTask 1 (Tired)18.2 score on a scaleStandard Deviation 3.92
Aim 1- VidaTalk Post-extubationAfter-Scenario Questionnaire (ASQ) ScoreTask 2 (Pain)19.5 score on a scaleStandard Deviation 2.81
Aim 1- VidaTalk Post-extubationAfter-Scenario Questionnaire (ASQ) ScoreTask 3 (Pain Rating)20.3 score on a scaleStandard Deviation 1.49
Aim 1- VidaTalk Post-extubationAfter-Scenario Questionnaire (ASQ) ScoreTask 4 (Pain Location)20.1 score on a scaleStandard Deviation 2.02
Aim 1- VidaTalk Post-extubationAfter-Scenario Questionnaire (ASQ) ScoreTask 5 (Pain Quality)20.7 score on a scaleStandard Deviation 0.949
Aim 1- VidaTalk Post-extubationAfter-Scenario Questionnaire (ASQ) ScoreTask 6 (Doctor)18.1 score on a scaleStandard Deviation 4.28
Aim 1- VidaTalk Post-extubationAfter-Scenario Questionnaire (ASQ) ScoreTask 7 (Word Draw)19.5 score on a scaleStandard Deviation 3.81
Aim 1- VidaTalk Post-extubationAfter-Scenario Questionnaire (ASQ) ScoreTask 8 (Typing)18.1 score on a scaleStandard Deviation 5.45
Aim 2 - VidaTalk IntubatedAfter-Scenario Questionnaire (ASQ) ScoreOverall ASQ17.6 score on a scaleStandard Deviation 4.61
Secondary

Communication Task Error Rate

Aims 1 & 2 - count of the number of errors recorded by video screen capture for each of 8 communication tasks. Individual patients ranged from 0 to 9 errors, however this measure contains no upper range per task as it is a count of actual observed errors committed by patients.

Time frame: Measured during 30-60 minute usability testing visit which occurs at study completion. This outcome applies only to Aim 1 & 2 arms.

Population: Aim 1 extubated patients. Using group 1 and group 2 summary data, 11 patients completed 82 tasks (6 were abandoned, 5 of these by one patient). Removing abandonments.

ArmMeasureGroupValue (NUMBER)
Aim 1- VidaTalk Post-extubationCommunication Task Error RateTask 1 (Tired).45 Errors
Aim 1- VidaTalk Post-extubationCommunication Task Error RateTask 5 (Pain Quality).40 Errors
Aim 1- VidaTalk Post-extubationCommunication Task Error RateTask 3 (Pain Rating).273 Errors
Aim 1- VidaTalk Post-extubationCommunication Task Error RateTask 6 (Doctor).20 Errors
Aim 1- VidaTalk Post-extubationCommunication Task Error RateTask 2 (Pain).09 Errors
Aim 1- VidaTalk Post-extubationCommunication Task Error RateTask 7 (Word Draw).22 Errors
Aim 1- VidaTalk Post-extubationCommunication Task Error RateTask 8 (Typing).50 Errors
Aim 1- VidaTalk Post-extubationCommunication Task Error RateTask 4 (Pain Location ).30 Errors
Aim 2 - VidaTalk IntubatedCommunication Task Error RateTask 8 (Typing).50 Errors
Aim 2 - VidaTalk IntubatedCommunication Task Error RateTask 1 (Tired)1.09 Errors
Aim 2 - VidaTalk IntubatedCommunication Task Error RateTask 2 (Pain)1.0 Errors
Aim 2 - VidaTalk IntubatedCommunication Task Error RateTask 3 (Pain Rating)1.0 Errors
Aim 2 - VidaTalk IntubatedCommunication Task Error RateTask 4 (Pain Location ).36 Errors
Aim 2 - VidaTalk IntubatedCommunication Task Error RateTask 5 (Pain Quality).63 Errors
Aim 2 - VidaTalk IntubatedCommunication Task Error RateTask 6 (Doctor)1.18 Errors
Aim 2 - VidaTalk IntubatedCommunication Task Error RateTask 7 (Word Draw).18 Errors
Secondary

Delirium/Coma -Free Days

Aim 3 -Delirium/coma-free days is defined as the number of days alive and free of delirium and coma during the 28-day study period. Delirium will be coded as present when a patient displays both features 1 and 2, and either 3 or 4 of the CAM-ICU (Confusion Assessment Method). Coma is defined as a RASS (Richmond Agitation-Sedation Scale ) assessment score of -4 or -5.

Time frame: Daily, from enrollment to 28 days post-enrollment

Population: Calculated as % days with delirium/total ICU days.

ArmMeasureValue (NUMBER)
Aim 3 - VidaTalk Tablet AppDelirium/Coma -Free Days8.26 percent days with delirium/total ICU day
Aim 3 - Attention-controlDelirium/Coma -Free Days8.54 percent days with delirium/total ICU day
p-value: 0.9395% CI: [0.19, 4.72]Mixed Models Analysis
Secondary

Ease of Communication at Extubation /ICU Discharge

Ease of Communication Scale -10-item likert scale total score ranging from 0-40. Each item is 0-4 likert scale, total score is sum of all items with higher scores indicating greater communication difficulty.

Time frame: measured at Extubation /ICU Discharge

Population: Extubated ICU patients

ArmMeasureValue (MEAN)Dispersion
Aim 3 - VidaTalk Tablet AppEase of Communication at Extubation /ICU Discharge23.19 score on a scaleStandard Deviation 11.31
Aim 3 - Attention-controlEase of Communication at Extubation /ICU Discharge27.23 score on a scaleStandard Deviation 10.46
p-value: 0.38t-test, 2 sided
Secondary

Electronic Visual Analogue Scale-validation Measure

(Aim4) visual analogue touch screen scale via android tablet with REDCap link. Not able to calculate because the touch screen scale was unreliable. Patients often needed assistance with the touch screen cursor for this experimental measure. We determined that pencil and paper analogue scale was superior for this patient population.

Time frame: Only measured at baseline, order of administration randomized before or after paper version

Population: Not able to calculate because the touch screen scale was unreliable. Patients often needed assistance with the touch screen cursor for this experimental measure. We determined that pencil and paper analogue scale was superior for this patient population.

Secondary

Family Communication Difficulty

Family Communication Survey administered to participant families. Sum of 9-items with each item rating 0 (not at all) to 4 (extremely difficult), resulting in a total summed score from 0 - 36. Higher scores indicate greater difficulty.

Time frame: baseline and extubation or discharge from the ICU

Population: Family Communication Survey baseline and extubation or discharge from the ICU

ArmMeasureGroupValue (MEAN)Dispersion
Aim 5-VidaTalk Efficacy in Family CaregiversFamily Communication DifficultyBaseline28.67 units on a scaleStandard Deviation 2.27
Aim 5-VidaTalk Efficacy in Family CaregiversFamily Communication DifficultyExtubation or Discharge from ICU33.67 units on a scaleStandard Deviation 1.6
Aim-5 Control GroupFamily Communication DifficultyBaseline25.62 units on a scaleStandard Deviation 1.59
Aim-5 Control GroupFamily Communication DifficultyExtubation or Discharge from ICU29.46 units on a scaleStandard Deviation 1.2
Secondary

Family Member Anxiety

(Aim 5) Hospital Anxiety and Depression Scale (HADS) Anxiety sub scale including 7 items each scored from 0-3 with total scores ranging from 0 - 21 with higher scores indicating higher levels of anxiety.

Time frame: Baseline, patient extubation or discharge from ICU, 1-month, 3-month, 6-month post-discharge

Population: Baseline

ArmMeasureGroupValue (MEAN)Dispersion
Aim 5-VidaTalk Efficacy in Family CaregiversFamily Member AnxietyPatient Extubation or Discharge from ICU8.67 units on a scaleStandard Deviation 4.44
Aim 5-VidaTalk Efficacy in Family CaregiversFamily Member Anxiety3-month6.83 units on a scaleStandard Deviation 4.92
Aim 5-VidaTalk Efficacy in Family CaregiversFamily Member Anxiety1-month4.86 units on a scaleStandard Deviation 4.06
Aim 5-VidaTalk Efficacy in Family CaregiversFamily Member Anxiety6-month6.80 units on a scaleStandard Deviation 5.63
Aim 5-VidaTalk Efficacy in Family CaregiversFamily Member AnxietyBaseline9.14 units on a scaleStandard Deviation 5.08
Aim-5 Control GroupFamily Member Anxiety6-month6.22 units on a scaleStandard Deviation 6.48
Aim-5 Control GroupFamily Member AnxietyBaseline9.29 units on a scaleStandard Deviation 4.83
Aim-5 Control GroupFamily Member AnxietyPatient Extubation or Discharge from ICU9.62 units on a scaleStandard Deviation 4.86
Aim-5 Control GroupFamily Member Anxiety1-month9.17 units on a scaleStandard Deviation 4.8
Aim-5 Control GroupFamily Member Anxiety3-month6.80 units on a scaleStandard Deviation 5.07
Comparison: Baselinep-value: 0.94t-test, 2 sided
Comparison: Patient Extubation or Discharge from ICUp-value: 0.89t-test, 2 sided
Comparison: 1-Monthp-value: 0.38t-test, 2 sided
Comparison: 3-Monthp-value: 0.63t-test, 2 sided
p-value: 0.73t-test, 2 sided
Secondary

Family Member Depression

(Aim 5). Hospital Anxiety and Depression Scale (HADS-D)- Depression Subscale including 7 items each scored from 0-3 with total scores ranging from 0 - 21 with higher scores indicating higher levels of depression symptoms.

Time frame: Baseline, patient extubation or discharge from ICU, 1-month, 3-month, 6-month post-discharge

Population: Aim 5 Family member depression HADS-D subscale

ArmMeasureGroupValue (MEAN)Dispersion
Aim 5-VidaTalk Efficacy in Family CaregiversFamily Member DepressionPatient Extubation or Discharge from ICU5.78 units on a scaleStandard Deviation 4.32
Aim 5-VidaTalk Efficacy in Family CaregiversFamily Member Depression3-month7.03 units on a scaleStandard Deviation 3.98
Aim 5-VidaTalk Efficacy in Family CaregiversFamily Member Depression1-month7.43 units on a scaleStandard Deviation 2.64
Aim 5-VidaTalk Efficacy in Family CaregiversFamily Member Depression6-month6.33 units on a scaleStandard Deviation 4.27
Aim 5-VidaTalk Efficacy in Family CaregiversFamily Member DepressionBaseline5.86 units on a scaleStandard Deviation 3.98
Aim-5 Control GroupFamily Member Depression6-month4.33 units on a scaleStandard Deviation 3.67
Aim-5 Control GroupFamily Member DepressionBaseline5.50 units on a scaleStandard Deviation 4.31
Aim-5 Control GroupFamily Member DepressionPatient Extubation or Discharge from ICU5.15 units on a scaleStandard Deviation 4.43
Aim-5 Control GroupFamily Member Depression1-month6.20 units on a scaleStandard Deviation 3.73
Aim-5 Control GroupFamily Member Depression3-month5.53 units on a scaleStandard Deviation 3.93
Comparison: Baselinep-value: 0.82t-test, 2 sided
Comparison: Patient extubation or discharge from ICUp-value: 0.84t-test, 2 sided
Comparison: 1-monthp-value: 0.96t-test, 2 sided
Comparison: 3-Monthp-value: 0.17t-test, 2 sided
p-value: 0.39t-test, 2 sided
Secondary

Family Satisfaction With Care in the Intensive Care Unit FS-ICU

(Aim3 )The Family Satisfaction with ICU Care (FS-ICU 24R) questionnaire overall satisfaction score is derived from questions 1 through 24 (26 items) and combines two subscale summary scores. The satisfaction with care summary score is derived from the questions numbered 1 through 14 (which consists of 16 questions because question 2 has parts a, b and c). The satisfaction with decision making summary score is derived from questions 15 through 24 (10 questions). All questions are coded as integers from 1 (worst) to 5 (best). Rescale the summary scores from 1 through 5 to 0 through 100 by subtracting 1 from the scores (so they can range from 0 to 4) and then multiplying each score by 25.

Time frame: One 10 minute survey will be given at patient's ICU discharge or extubation

Population: Total score on the Family Satisfaction in the Intensive Care Unit Survey (FS-ICU) completed by designated family caregiver-support person.

ArmMeasureValue (MEAN)Dispersion
Aim 3 - VidaTalk Tablet AppFamily Satisfaction With Care in the Intensive Care Unit FS-ICU81.8 score on a scaleStandard Deviation 13.8
Aim 3 - Attention-controlFamily Satisfaction With Care in the Intensive Care Unit FS-ICU92.4 score on a scaleStandard Deviation 7.2
p-value: 0.07t-test, 2 sided
Secondary

Mean Daily Sedation Exposure

Used in Aim 3 only. Calculation of benzodiazepine and morphine equivalents (for opiates) using hospital conversion charts (pharmacy conversion chart). All benzo IV doses were converted to Lorazepam IV doses. All opioid IV doses were converted to morphine IV doses. All benzo oral doses were converted to Lorazepam oral doses. All opioid oral doses were converted to morphine oral doses. Oral doses were converted to IV equivalents. Summed doses of Lorazepam IV and morphine IV were calculated for each study day for each patient. Doses were converted to milligrams per kilogram based on the patient's body weight. Higher numbers indicate greater sedation and/or opiate exposure.

Time frame: Daily post-randomization until extubation or ICU discharge up to maximum of 28 days in the ICU daily in ICU

Population: P-values were derived from mixed-effects regression using rank-based sedation exposure

ArmMeasureGroupValue (MEAN)Dispersion
Aim 3 - VidaTalk Tablet AppMean Daily Sedation ExposureBenzo (mg/kg).01 mg/kgStandard Deviation 0.05
Aim 3 - VidaTalk Tablet AppMean Daily Sedation ExposureMorphine (mg/kg).84 mg/kgStandard Deviation 2.1
Aim 3 - Attention-controlMean Daily Sedation ExposureBenzo (mg/kg).008 mg/kgStandard Deviation 0.02
Aim 3 - Attention-controlMean Daily Sedation ExposureMorphine (mg/kg).24 mg/kgStandard Deviation 0.5
Comparison: Benzodiazepine exposurep-value: 0.02Mixed Models Analysis
Comparison: Opioid Exposurep-value: 0.291Mixed Models Analysis
Secondary

Mean Patient Frustration With Communication

Aim 3 - This will be the calculated mean of the daily Communication Frustration scale - a single item scale reported by the patient, ranging from 0 not frustrating to 4 extremely frustrating

Time frame: Daily post-randomization until extubation or ICU discharge up to maximum of 28 days in the ICU

Population: This information is for Aim 3 only.

ArmMeasureValue (MEAN)Dispersion
Aim 3 - VidaTalk Tablet AppMean Patient Frustration With Communication3.14 units on a scaleStandard Deviation 1.89
Aim 3 - Attention-controlMean Patient Frustration With Communication3.53 units on a scaleStandard Deviation 0.17
p-value: 0.1Effect size
p-value: 0.1t-test, 2 sided
Secondary

Mean Patient Reported Anxiety Score Using Visual Analogue Scale

Aim 3 - Calculated mean of daily measure by patient mark (x) or point on the Visual Analogue Scale for anxiety, a 100 mm vertical line ranging from 0 (not anxious at all) to 10 (most anxious I've ever been).

Time frame: Daily post-randomization until extubation or ICU discharge up to maximum of 28 days in the ICU

Population: This Secondary Outcome is for participants in Aim 3 only.

ArmMeasureValue (MEAN)Dispersion
Aim 3 - VidaTalk Tablet AppMean Patient Reported Anxiety Score Using Visual Analogue Scale5.55 score on a scaleStandard Deviation 6.54
Aim 3 - Attention-controlMean Patient Reported Anxiety Score Using Visual Analogue Scale6.02 score on a scaleStandard Deviation 6.07
p-value: 0.55t-test, 2 sided
Secondary

Number of Participants That Responded Yes to Having Communication Difficulty at Extubation or ICU Discharge

Measured as a single item : Question asked was - Presence of communication difficulty in the last few days? with answers being Yes or No

Time frame: measured at Extubation /ICU Discharge

Population: Extubated ICU patients

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Aim 1- VidaTalk Post-extubationNumber of Participants That Responded Yes to Having Communication Difficulty at Extubation or ICU Discharge0 Participants
Aim 2 - VidaTalk IntubatedNumber of Participants That Responded Yes to Having Communication Difficulty at Extubation or ICU Discharge0 Participants
Aim 3 - VidaTalk Tablet AppNumber of Participants That Responded Yes to Having Communication Difficulty at Extubation or ICU Discharge14 Participants
Aim 3 - Attention-controlNumber of Participants That Responded Yes to Having Communication Difficulty at Extubation or ICU Discharge23 Participants
Aim 5-VidaTalk Efficacy in Family CaregiversNumber of Participants That Responded Yes to Having Communication Difficulty at Extubation or ICU Discharge0 Participants
p-value: 0.0595% CI: [0.05, 1.01]t-test, 2 sided
Comparison: Adjusted for baseline communication difficultyp-value: 0.195% CI: [0.06, 1.3]Regression, Linear
Secondary

Observed Task Completion Time (in Seconds)

Aims 1 & 2 - This is the time, measured in seconds, on the screen capture recording beginning with the communication task command to patient completion of the communication task or message to patient completion of each of the 8 communication tasks on the usability test, calculated from the screen capture recordings

Time frame: Measured during 30-60 minute usability testing visit which occurs at study completion

Population: This is the time, measured in seconds, on the screen capture recording beginning with the communication task command to patient completion of the communication task or message to patient completion of each of the 8 communication tasks on the usability test, calculated from the screen capture recordings

ArmMeasureGroupValue (MEAN)Dispersion
Aim 1- VidaTalk Post-extubationObserved Task Completion Time (in Seconds)Task 1 (Tired)64.27 secondsStandard Deviation 69.02
Aim 1- VidaTalk Post-extubationObserved Task Completion Time (in Seconds)Task 2 (Pain)16.73 secondsStandard Deviation 13.06
Aim 1- VidaTalk Post-extubationObserved Task Completion Time (in Seconds)Task 3 (Pain Rating)26.6 secondsStandard Deviation 26.71
Aim 1- VidaTalk Post-extubationObserved Task Completion Time (in Seconds)Task 4 (Pain Location)25.3 secondsStandard Deviation 34.19
Aim 1- VidaTalk Post-extubationObserved Task Completion Time (in Seconds)Task 5 (Pain Quality)44.0 secondsStandard Deviation 75.83
Aim 1- VidaTalk Post-extubationObserved Task Completion Time (in Seconds)Task 6 (Doctor)53.9 secondsStandard Deviation 35.86
Aim 1- VidaTalk Post-extubationObserved Task Completion Time (in Seconds)Task 7 (Word Draw)22.22 secondsStandard Deviation 25.06
Aim 1- VidaTalk Post-extubationObserved Task Completion Time (in Seconds)Task 8 (Typing)57.7 secondsStandard Deviation 61.18
Aim 2 - VidaTalk IntubatedObserved Task Completion Time (in Seconds)Task 8 (Typing)73.3 secondsStandard Deviation 53.4
Aim 2 - VidaTalk IntubatedObserved Task Completion Time (in Seconds)Task 1 (Tired)117.45 secondsStandard Deviation 107.29
Aim 2 - VidaTalk IntubatedObserved Task Completion Time (in Seconds)Task 5 (Pain Quality)52.73 secondsStandard Deviation 49.26
Aim 2 - VidaTalk IntubatedObserved Task Completion Time (in Seconds)Task 2 (Pain)80.0 secondsStandard Deviation 143.62
Aim 2 - VidaTalk IntubatedObserved Task Completion Time (in Seconds)Task 7 (Word Draw)37.55 secondsStandard Deviation 25.28
Aim 2 - VidaTalk IntubatedObserved Task Completion Time (in Seconds)Task 3 (Pain Rating)74.0 secondsStandard Deviation 64.35
Aim 2 - VidaTalk IntubatedObserved Task Completion Time (in Seconds)Task 6 (Doctor)100.0 secondsStandard Deviation 75.51
Aim 2 - VidaTalk IntubatedObserved Task Completion Time (in Seconds)Task 4 (Pain Location)34.82 secondsStandard Deviation 34.19
Secondary

Patient Satisfaction With Care

A 24-item survey with lower scores indicating greater satisfaction with care.

Time frame: Measured at extubation or discharge from ICU which ever comes first

Population: Patient Satisfaction with Care at extubation /ICU discharge single item likert type scale 1 (very dissatisfied) to 5 (very satisfied)

ArmMeasureValue (MEAN)Dispersion
Aim 3 - VidaTalk Tablet AppPatient Satisfaction With Care4.45 units on a scaleStandard Deviation 1.01
Aim 3 - Attention-controlPatient Satisfaction With Care4.56 units on a scaleStandard Deviation 0.92
p-value: 0.71t-test, 2 sided
Secondary

Patient Satisfaction With Communication Task Ease

Aims 1 & 2 - a single item from the After Scenario Questionnaire (ASQ) of patient's self rating of satisfaction with the ease of completing each of 8 communication tasks on the usability test. Question asked of patients was Overall, I am satisfied with the ease of completing this task. 1-strongly disagree 7-strongly agree. Higher scores indicated greater satisfaction with the ease of completing the task.

Time frame: Measured during 30-60 minute usability testing visit which occurs at study completion

Population: Aim 1 Extubated patients - mean Task Ease Rating Aim 2 Intubated patients - mean Task Ease Rating

ArmMeasureGroupValue (MEAN)Dispersion
Aim 1- VidaTalk Post-extubationPatient Satisfaction With Communication Task EaseTask 1 (Tired)5.7 score on a scaleStandard Deviation 1.85
Aim 1- VidaTalk Post-extubationPatient Satisfaction With Communication Task EaseTask 2 (Pain)6.7 score on a scaleStandard Deviation 0.647
Aim 1- VidaTalk Post-extubationPatient Satisfaction With Communication Task EaseTask 3 (Pain Rating)6.7 score on a scaleStandard Deviation 0.675
Aim 1- VidaTalk Post-extubationPatient Satisfaction With Communication Task EaseTask 4 (Pain Location)6.7 score on a scaleStandard Deviation 0.675
Aim 1- VidaTalk Post-extubationPatient Satisfaction With Communication Task EaseTask 5 (Pain Quality)6.9 score on a scaleStandard Deviation 0.316
Aim 1- VidaTalk Post-extubationPatient Satisfaction With Communication Task EaseTask 6 (Doctor)5.8 score on a scaleStandard Deviation 1.68
Aim 1- VidaTalk Post-extubationPatient Satisfaction With Communication Task EaseTask 7 (Draw Word)6.9 score on a scaleStandard Deviation 0.316
Aim 1- VidaTalk Post-extubationPatient Satisfaction With Communication Task EaseTask 8 (Typing)5.9 score on a scaleStandard Deviation 2.08
Aim 2 - VidaTalk IntubatedPatient Satisfaction With Communication Task EaseOverall Ease5.82 score on a scaleStandard Deviation 1.6
Secondary

Percentage of Patients Scoring in the Calm Range During Study Days on Richmond Agitation Sedation Score

The Richmond Agitation Sedation Scale, a 10-level observational rating of agitation-sedation motor activity ranging from +4 'combative' to -5 unresponsive, with 0 as calm. Since this is a categorical measure, we compared proportion of patients with RASS in -1 to +1 (calm) range during study days.

Time frame: Daily post-randomization until extubation or ICU discharge up to maximum of 28 days in the ICU

Population: Since this is a categorical measure, we compared percentage of patients with RASS in -1 to +1 (calm) range during study days.

ArmMeasureValue (NUMBER)
Aim 3 - VidaTalk Tablet AppPercentage of Patients Scoring in the Calm Range During Study Days on Richmond Agitation Sedation Score81.48 percentage of participants in calm range
Aim 3 - Attention-controlPercentage of Patients Scoring in the Calm Range During Study Days on Richmond Agitation Sedation Score77.78 percentage of participants in calm range
p-value: 0.32Chi-squared
Secondary

Post-traumatic Stress Symptoms: Impact of Events Scale-revised (IES-R)

(Aim 5) Impact of Events Scale-revised. The IES-R is a 22-item self-report instrument with three subscales including intrusion (8 items), avoidance (8 items), and hyperarousal (6 items). The respondent is asked to report the degree of distress experienced for each item in the past 7 days. Each item is scored on a five-point Likert scale (0, not at all; 1, rarely; 2, occasionally; 3, fairly often; and 4, often) and total scores range from 0 to 88. Higher scores are representative of greater distress.

Time frame: 1-month, 3-month, 6-month post-discharge

Population: Impact of events scale median/IQR

ArmMeasureGroupValue (MEDIAN)
Aim 5-VidaTalk Efficacy in Family CaregiversPost-traumatic Stress Symptoms: Impact of Events Scale-revised (IES-R)1-month21.5 units on a scale
Aim 5-VidaTalk Efficacy in Family CaregiversPost-traumatic Stress Symptoms: Impact of Events Scale-revised (IES-R)3-months21 units on a scale
Aim 5-VidaTalk Efficacy in Family CaregiversPost-traumatic Stress Symptoms: Impact of Events Scale-revised (IES-R)6-months23 units on a scale
Aim-5 Control GroupPost-traumatic Stress Symptoms: Impact of Events Scale-revised (IES-R)1-month30.5 units on a scale
Aim-5 Control GroupPost-traumatic Stress Symptoms: Impact of Events Scale-revised (IES-R)3-months27.5 units on a scale
Aim-5 Control GroupPost-traumatic Stress Symptoms: Impact of Events Scale-revised (IES-R)6-months26 units on a scale
Comparison: 1-monthp-value: 0.26Wilcoxon (Mann-Whitney)
Comparison: 3-monthp-value: 0.25Wilcoxon (Mann-Whitney)
Comparison: 6-monthp-value: 0.79Wilcoxon (Mann-Whitney)
Secondary

System Usability Scale (SUS) -Adapted

Aims 1 & 2, System Usability Scale is 13-item likert type scale with item ratings of 1 'strongly agree' to 7 'strongly disagree' to obtain the patient's rating of overall usability of the VidaTalk application, total scores range from 13 to 91 Note: This is different from the standard 10-item SUS that uses a 5-point scale, with scores ranging 0-100.

Time frame: Measured during 30-60 minute usability testing visit which occurs at study completion

Population: Note: This is different from the standard 10-item SUS that uses a 5-point scale, with scores ranging 0-100.~Aim 3 and 5 were not addressed with this question.

ArmMeasureValue (MEAN)Dispersion
Aim 1- VidaTalk Post-extubationSystem Usability Scale (SUS) -Adapted82.5 units on a scaleStandard Deviation 5.91
Aim 2 - VidaTalk IntubatedSystem Usability Scale (SUS) -Adapted68.5 units on a scaleStandard Deviation 12.37
Secondary

Total Error Rate

Aims 1 & 2 - calculated mean of the total number of errors recorded by video screen capture divided by the number of communication tasks completed (8 maximum) Aim 1 extubated patients. Using group 1 and group 2 summary data, 11 patients completed 82 tasks (6 were abandoned, 5 of these by one patient). Removing abandonments, total number of errors = 25/ 82 tasks = 0.30 error rate. Aim 2 intubated patients. 11 patients completed 69 tasks (18 were abandoned; 1 task was refused). Removing abandonments, total number of errors = 60/ 69 tasks = 0.87error rate.

Time frame: Measured during 30-60 minute usability testing visit which occurs at study completion

Population: Aim 1 extubated patients. Using group 1 and group 2 summary data, 11 patients completed 82 tasks (6 were abandoned, 5 of these by one patient).~Aim 2 intubated patients. 11 patients completed 69 tasks (18 were abandoned; 1 task was refused).

ArmMeasureValue (NUMBER)
Aim 1- VidaTalk Post-extubationTotal Error Rate0.30 error rate
Aim 2 - VidaTalk IntubatedTotal Error Rate0.87 error rate

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026